What does BioVie do?
BioVie Inc. is a clinical-stage biotechnology company listed on the Nasdaq Capital Market under BIVI. It is developing therapies for neurological and neurodegenerative disorders and for complications of advanced liver disease. The company’s current identity is built around two drug assets: bezisterim, an orally administered small molecule being studied in Parkinson’s disease, Long COVID, Alzheimer’s disease and aging-related biology; and BIV201, a continuous-infusion formulation of terlipressin for refractory ascites caused by liver cirrhosis. BioVie presents its broader purpose as unlocking longevity science to transform how people live, but its economic reality remains that of a pre-commercial drug developer.
One operating segment, several clinical bets
BioVie reports as one operating segment because management allocates resources across a compact development organization rather than operating separate commercial divisions. That accounting simplicity should not obscure the portfolio’s scientific diversity. Bezisterim is intended to reduce inflammation and improve insulin sensitivity without broad immunosuppression, while BIV201 addresses fluid accumulation in decompensated cirrhosis through sustained terlipressin exposure. The fiscal 2025 Form 10-K is the clearest official source for the company’s business description, patents, trial history and risk factors.
How does BioVie plan to make money?
BioVie has not yet generated product sales. Its future business model therefore depends on converting clinical evidence into regulatory approvals and then monetizing approved indications through direct commercialization, licensing, co-development or partnership arrangements. Management has not committed to one universal route for every program. That flexibility is rational for a small biotechnology company because commercialization requirements differ sharply between a neurologic drug used broadly in outpatient care and an infusion therapy used in advanced liver disease.
No product revenue means financing is part of the model
Until a drug is approved and launched, BioVie’s operating cash inflow comes mainly from equity financing, warrant exercises, interest income and research reimbursements. The $13.1 million federally funded Long COVID award reduces the company-funded cost of that program, but reimbursement is not product revenue and does not create a repeatable commercial margin. BioVie’s nine-month FY2026 cash-flow statement illustrates the structure: operations used $14.9 million, while financing activities supplied $10.5 million. The business model is therefore inseparable from access to capital markets.
What could commercialization economics look like?
| Potential revenue route | Economic logic | Main dependency |
|---|---|---|
| Direct product sales | BioVie retains more gross economics but must build medical, market-access and sales capabilities. | Approval, reimbursement, manufacturing scale and launch capital. |
| Licensing | Upfront, milestone and royalty economics may reduce BioVie’s commercialization burden. | Partner interest and strength of clinical data. |
| Co-development | Costs and future returns can be shared while preserving some strategic control. | Negotiated cost sharing, territory rights and governance. |
| BIV201 royalties | Future net sales would be subject to contractual royalty obligations described in filings. | Successful pivotal development and approval in ascites. |
Which clinical programs matter most?
The portfolio is concentrated around bezisterim. That creates efficiency because one molecule can generate evidence across several conditions, but it also creates correlated risk: a safety, manufacturing or mechanism concern could affect multiple programs. BIV201 provides a mechanistically separate option in liver disease, although it is earlier in its pivotal-development journey and has its own funding requirements.
Bezisterim is a single-molecule platform thesis
Bezisterim is described as orally bioavailable, able to cross the blood-brain barrier and designed to modulate inflammatory and insulin-resistance pathways, including ERK, NF-κB and TNF-α signaling. The strategic thesis is that chronic neuroinflammation and metabolic dysfunction contribute to several age-related disorders. If the mechanism translates consistently, one manufacturing and safety package could support multiple indication-specific programs. If it does not, portfolio diversification is less substantial than the number of trials implies.
Current program status and decision points
| Program | Official status | Nearest decision point | Research implication |
|---|---|---|---|
| Parkinson’s disease | Phase 2 SUNRISE-PD last-patient evaluation completed | Topline data targeted for Q3 2026 | The readout can influence dose, endpoints and feasibility of later-stage development. |
| Long COVID | Approximately 200 participants fully enrolled | Topline data expected in late summer 2026 | Grant funding lowers net cost, but clinical relevance and regulatory pathways remain uncertain. |
| Alzheimer’s disease | Prior Phase 3 analysis materially affected by protocol deviations at 15 sites | Define a credible future development and regulatory strategy | Evidence quality and trial-control systems matter as much as biological signal. |
| Refractory ascites | Phase 2 experience completed; FDA guidance received for later-stage design | Finance and initiate a registrational program | Potential differentiation must be weighed against infusion logistics and trial cost. |
How did BioVie’s strategy evolve?
BioVie’s history is best understood as a sequence of asset acquisitions, regulatory milestones and portfolio reprioritizations. The important question is not when each event occurred, but how it changed the company’s present concentration, financing needs and credibility requirements.
-
2016BIV201 entered the portfolio. BioVie acquired LAT Pharma and the continuous-infusion terlipressin program, establishing the original liver-disease strategy.
-
2016–2018Regulatory designations improved development positioning. The FDA granted orphan-drug designations for ascites and hepatorenal syndrome, while BIV201 also obtained Fast Track status.
-
2021NeurMedix assets transformed the company. The acquisition added bezisterim and shifted BioVie from a single liver-disease program toward neurodegeneration and inflammation.
-
2023The Alzheimer’s Phase 3 dataset exposed execution risk. Protocol deviations at 15 sites forced exclusions and left the modified intent-to-treat population at 81 patients, far below the planned scale.
-
2024–2025BioVie narrowed near-term focus and repaired the balance sheet. R&D fell from $23.1 million in FY2024 to $9.3 million in FY2025, and the company repaid its secured note.
-
2026Two controlled readouts became the central catalysts. SUNRISE-PD completed patient evaluations and ADDRESS-LC reached full enrollment, concentrating attention on data quality and cash runway.
What the timeline says about strategy today
The company has moved from a narrow orphan-liver-disease thesis to a broader inflammation-and-longevity thesis centered on bezisterim. That broadening increased addressable-market optionality, but it also raised the bar for trial execution. The Alzheimer’s experience shows why site monitoring, protocol compliance and prespecified analysis populations are now material strategic assets. For a small developer, operational reliability can determine whether scientific hypotheses become financeable programs.
What does BioVie’s latest quarter show?
The quarter ended March 31, 2026 shows a company spending more rapidly as two late-stage Phase 2 programs approached readouts. The Q3 FY2026 Form 10-Q reported no revenue, a $5.3 million quarterly net loss and $13.1 million of cash. The period is more informative as a measure of burn and trial intensity than as an earnings comparison.
Quarterly and nine-month financial snapshot
| Metric | Q3 FY2026 | Q3 FY2025 | 9M FY2026 |
|---|---|---|---|
| R&D expense | $3.2M | $1.3M | $10.4M |
| G&A expense | $2.2M | $1.6M | $6.4M |
| Operating expenses | $5.4M | $3.0M | $16.9M |
| Net loss | $(5.3M) | $(2.8M) | $(16.4M) |
| Basic loss per share | $(0.70) | $(1.51) | $(2.35) |
| Operating cash flow | Not separately disclosed for quarter | Not separately disclosed for quarter | $(14.9M) |
Where did R&D spending go?
SUNRISE-PD accounted for $6.1 million of nine-month study spending, compared with $2.6 million in the prior-year period. The Long COVID program recorded $4.6 million of gross costs and $4.1 million of reimbursements, leaving a much smaller net burden. This distinction is important: gross trial activity can be high even when grant reimbursement lowers reported net R&D.
Clinical optionality and trial execution define BioVie’s competitive position
A clinical-stage company does not possess a traditional moat based on scale or customer switching costs. BioVie’s defensibility rests on patents, know-how, regulatory designations, mechanistic differentiation and the quality of evidence it can generate. Bezisterim has patent protection in the United States and several other jurisdictions. BIV201 combines terlipressin, an established active agent, with a continuous-infusion delivery concept and protected liquid formulations. These are potential barriers, not proof of commercial advantage.
What counts as a moat before approval?
The scorecard is an analytical interpretation of official disclosures, not a credit rating. It highlights a central VRIO-style issue: a patented scientific resource creates durable value only if the company can validate it, protect it, finance it and organize a regulatory and commercial system around it.
Which competitors pressure the programs?
| Area | Named or relevant competitors | Competitive pressure |
|---|---|---|
| Alzheimer’s disease | Biogen and Eli Lilly, among a broader field | Approved or advanced disease-modifying therapies raise evidence, safety and reimbursement expectations. |
| Parkinson’s disease | Large pharmaceutical companies and numerous clinical-stage developers | BioVie must show a clinically meaningful effect beyond symptomatic standards of care. |
| Long COVID | Fragmented academic, government and biotechnology programs | Heterogeneous symptoms and evolving diagnostic definitions complicate endpoints and patient selection. |
| Ascites and cirrhosis complications | Ocelot Bio; standard diuretics and paracentesis; approved terlipressin in hepatorenal syndrome | BIV201 must prove that its infusion approach improves outcomes enough to justify logistics and cost. |
How financially strong is BioVie?
BioVie entered the final quarter of FY2026 with a cleaner debt position than one year earlier, but liquidity remains limited relative to the cost of multiple clinical programs. Cash was $13.1 million at March 31, 2026, current assets were $16.9 million and current liabilities were $1.7 million, producing approximately $15.2 million of working capital. The balance sheet had no large secured note outstanding, yet the accumulated deficit had reached $368.6 million.
Liquidity, losses and going-concern language
| Balance-sheet item | March 31, 2026 | June 30, 2025 | Interpretation |
|---|---|---|---|
| Cash | $13.1M | $17.5M | Declined as trial spending exceeded financing inflows. |
| Current assets | $16.9M | $20.7M | Includes a $2.2 million grant receivable at March 2026. |
| Total liabilities | $1.9M | $2.6M | Low reported debt burden improves near-term flexibility. |
| Stockholders’ equity | $15.6M | $19.0M | Ongoing losses continue to consume contributed capital. |
| Accumulated deficit | $(368.6M) | $(352.1M) | Reflects the cumulative cost of development without commercial revenue. |
Management’s filings state that recurring losses, negative operating cash flow and the absence of revenue create substantial doubt about the company’s ability to continue as a going concern without additional capital. This does not predict insolvency on a specific date; it signals that the current cash balance is not sufficient to finance the full development plan indefinitely.
Capital structure and dilution capacity
The S-3 registers up to $300 million of securities for potential future issuance. A shelf registration is financing flexibility, not a commitment to issue the full amount. Nevertheless, the large warrant and option overhang means per-share valuation must model both operating cash needs and possible dilution.
Who owns BioVie, and how does governance matter?
BioVie has one-vote-per-share common stock and no cumulative voting. That is simpler than a dual-class structure, but ownership can change quickly because the company is small and equity issuance is frequent. The latest proxy reported modest insider ownership as of September 22, 2025; a later Schedule 13D showed that Chief Executive Officer Cuong Do crossed the 5% beneficial-ownership threshold after including exercisable equity instruments.
Economic ownership versus voting influence
| Holder or group | Reported position | Source period | Why it matters |
|---|---|---|---|
| Cuong Do, CEO | 399,018 shares beneficially owned; 5.03% | March 25, 2026 Schedule 13D | Includes exercisable options and warrants, aligning leadership with equity value while making compensation dilution relevant. |
| Directors and executive officers as a group | 65,312 shares; 0.9% | September 22, 2025 proxy record date | The proxy snapshot predates the CEO’s later 13D and illustrates how quickly beneficial ownership can change. |
| Common stockholders | One vote per share; no cumulative voting | June 2026 S-3 | Control is based on economic ownership rather than superior-vote shares. |
| Equity plan | 3.1 million-share plan authorization approved in 2025 | 2025 annual meeting | Supports retention but expands the pool available for employee and director equity awards. |
What governance should researchers monitor?
The board’s most important functions are capital allocation, clinical oversight and credibility after the Alzheimer’s trial deviations. Researchers should watch whether compensation metrics reward verifiable clinical execution, whether financing terms protect existing holders, and whether the board adds expertise in late-stage development, regulatory affairs and commercialization. In a pre-revenue biotechnology company, governance quality often appears first in protocol discipline and financing choices rather than dividend or acquisition policy.
What opportunities and risks could change the BioVie story?
The opportunity set is unusually binary. A convincing Parkinson’s or Long COVID readout could validate bezisterim’s mechanism, support regulatory discussions and improve partnering or financing leverage. Conversely, ambiguous efficacy, safety concerns or another operational failure could reduce the value of multiple indications at once. BIV201 offers independent scientific optionality, but it also requires substantial new capital before a registrational program can create commercial value.
The most important risk channels
Opportunity and risk transmission into financial statements
| Event | Likely first financial effect | Longer-term valuation effect |
|---|---|---|
| Positive controlled trial | Higher R&D and regulatory spending | Higher probability of approval, partnering and future revenue. |
| Ambiguous or negative trial | Possible impairment of program value and restructuring costs | Lower terminal cash-flow probability and reduced financing leverage. |
| New partnership | Potential upfront cash and cost sharing | Lower funding burden, but BioVie may surrender part of future economics. |
| Equity financing | Higher cash and stockholders’ equity | Longer runway offset by lower ownership per existing share. |
| Pivotal BIV201 launch | Sharp increase in clinical and manufacturing expenditure | Creates a second, mechanistically independent value path if adequately funded. |
What is the key takeaway for valuation and research?
A conventional discounted cash-flow model is not sufficient for BioVie unless it is converted into a probability-adjusted pipeline model. There is no stable revenue base to extrapolate. Each indication needs an explicit probability of technical and regulatory success, launch timing, addressable patient population, pricing and reimbursement assumption, market penetration curve, gross margin, selling cost and required future R&D. Those program values must then be reduced by corporate cash burn, expected financing and dilution.
Which KPIs matter most next?
- SUNRISE-PD endpoint results, safety profile and biomarker coherence.
- ADDRESS-LC effect size, missing-data handling and prespecified subgroup consistency.
- Quarterly R&D expense, operating cash use and unrestricted cash.
- Grant reimbursements received versus Long COVID gross trial costs.
- Regulatory feedback defining pivotal designs and sample sizes.
- Common shares, warrants and options on a fully diluted basis.
- Any partnership terms that exchange development funding for future economics.
- Progress toward financing a registrational BIV201 program.
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.